ACT Biotech submits SPA for Telatinib Phase 3 trial with FDA
Reportedly, the Phase 3 Telatinib trial will compare Telatinib in conjunction with a standard regimen of chemotherapy versus chemotherapy alone in advanced stomach cancer patients. ACT Biotech said
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.